AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00828308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
Study NCT00828308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*
Study NCT03291886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT03291886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entinostat(Placebo)
Description: Given PO
Study NCT03291886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT03291886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Given PO
Study NCT02643862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair
Description: Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
Study NCT02643862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03771430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis education, exercise and CBT
Description: Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results
Study NCT03771430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Standard total knee arthroplasty will be performed.
Study NCT03771430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Standard total knee arthroplasty will be performed.
Study NCT04975022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N11005
Description: oral insulin N11005, 300IU, p.o.
Study NCT04975022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolin R
Description: reference preparation Novolin R, 0.1 IU/Kg, i.h.
Study NCT03047928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
Study NCT03047928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1/IDO peptide vaccine
Description: The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
Study NCT01668082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection of a brain tumor
Description: The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
Study NCT03949790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB and Intercostal nerve block
Description: Erector spinae plane block + Intercostal nerve block
Study NCT03949790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block
Description: Intercostal nerve block
Study NCT01755702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01645384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study NCT01645384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study NCT02980848 — intervention group
Intervention type: OTHER
Intervention: Screening digital mammography
Description: Screening with digital mammography alone
Study NCT02980848 — intervention group
Intervention type: OTHER
Intervention: Screening digital breast tomosynthesis
Description: Screening with digital mammography plus digital breast tomosynthesis
Study NCT02980848 — intervention group
Intervention type: OTHER
Intervention: Screening breast magnetic resonance imaging
Description: Screening with digital mammography plus breast magnetic resonance imaging
Study NCT02980848 — intervention group
Intervention type: OTHER
Intervention: Diagnostic mammography
Description: Pre-operative diagnostic work-up with mammography alone
Study NCT02980848 — intervention group
Intervention type: OTHER
Intervention: Pre-operative breast magnetic resonance imaging
Description: Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
Study NCT02210351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI test
Study NCT03097042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer any further manipulation
Description: The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
Study NCT03097042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer with catheter Manipulation
Description: catheter rotation during withdrawal
Study NCT01223807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing training
Description: The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
Study NCT03718338 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation
Description: Undergo clinical evaluations
Study NCT03718338 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04639934 — intervention group
Intervention type: GENETIC
Intervention: MeTree
Description: Software program collecting family health history and generating clinical decision support for risk-based preventive care
Study NCT03843957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-CRC
Description: mPATH-CRC is a self-administered iPad program that patients eligible for CRC screening use in primary care clinics to help them receive CRC screening.
Study NCT03843957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPATH-Checkin
Description: The mPATH-CheckIn program includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
Study NCT03843957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high touch Implementation strategy
Description: The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~* Clinic champion identified.~* Study team meeting with clinic champion~* Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~* Monthly program usage report sent to clinic champions~* Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~* Implementation adaptations as needed for clinic flow~* Goal-triggered follow-up on-site trainings~* Additional on-site trainings as requested.~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard
Study NCT03843957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high touch Implementation strategy
Description: The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~* Clinic champion identified.~* Study team meeting with clinic champion~* Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~* Monthly program usage report sent to clinic champions~* Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~* Implementation adaptations as needed for clinic flow~* Goal-triggered follow-up on-site trainings~* Additional on-site trainings as requested.~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard
Study NCT01755702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol + caffeine formulation
Description: experimental paracetamol + caffeine formulation
Study NCT01755702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen marketed formulation
Description: ibuprofen marketed formulation
Study NCT01755702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol marketed formulation
Description: Paracetamol marketed formulation
Study NCT00448890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK729327
Description: Tablets
Study NCT00448890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK729327 Matching placebo - Tablets
Study NCT00758459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: oral tablet, 75 mg, twice daily during 6 weeks
Study NCT00758459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing to match AZD1236
Study NCT04842578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross- Section of CT Guided Anatomic Segmentectomy
Description: The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.
Study NCT04842578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D simulation Guided Anatomic Segmentectomy
Description: The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
Study NCT00691132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenethyl isothiocyanate
Description: Given orally
Study NCT00691132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT01238640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Code STD
Description: 2 mg Single-dose of experimental nicotine product coded STD
Study NCT01238640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Code STE
Description: 2 mg Single-dose of experimental nicotine product coded STE
Study NCT01238640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Microtab
Description: A comparative 2 mg Single-dose of marketed tablet
Study NCT04440839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine specialty consultation
Description: Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
Study NCT01480596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10mg/kg IV infusion
Study NCT01480596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo IV infusion
Study NCT01299090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator
Description: two treatments spaced 30 days apart
Study NCT00298922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg tablets orally thrice weekly for 24 weeks
Study NCT00298922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet orally thrice weekly for 24 weeks
Study NCT02203708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Program for Mother with BPD (SuPMother-B).
Description: The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids.
Study NCT04182763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
Study NCT04182763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CoA-Z
Description: People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
Study NCT04182763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
Study NCT02307591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
Study NCT02307591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care + Amiodarone
Description: This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day
Study NCT03670225 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Invia Motion Endure
Description: NPWT Invia Motion Endure
Study NCT00942617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 40 mg non-enteric coated ASA once daily for 21 + or - 2 days
Study NCT01154478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet rich in omega-3 fatty acids
Description: fish at least 3 times per week, large leaf vegetables
Study NCT01154478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet rich in polyphenols
Description: extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
Study NCT01154478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
Study NCT01154478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet rich in omega-3 and polyphenols
Description: Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
Study NCT04359771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow micro-pulse laser
Description: applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
Study NCT04359771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode micro-pulse laser
Description: applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
Study NCT01498822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
Study NCT01498822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: 150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
Study NCT03262558 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients will undergo standard clinical routine practice in this indication
Study NCT03843957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low touch Implementation Strategy
Description: Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard
Study NCT03843957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low touch Implementation Strategy
Description: Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard
Study NCT00535522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-285 Dose Escalation Cohorts
Description: TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
Study NCT00535522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-285 Recommended Phase 2 Dosing Cohort
Description: Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
Study NCT03393858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
Study NCT03393858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK Immunotherapy
Description: Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
Study NCT03393858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotron RF-8EX
Description: Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
Study NCT00774358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
Study NCT04435613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: protective mechanical ventilation strategies
Description: 1. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
Study NCT02507206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAR 0-100A
Description: 15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
Study NCT02507206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAR 0-100A
Description: 15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.